Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
(NY:
GSK
)
38.95
+0.55 (+1.43%)
Official Closing Price
Updated: 4:10 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
2 Best Artificial Intelligence Stocks to Buy in October
October 13, 2024
These companies could have more growth ahead than investors realize.
Via
The Motley Fool
Topics
Artificial Intelligence
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
October 11, 2024
GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future growth persist as challenges with its drug pipeline remain.
Via
Benzinga
Topics
Lawsuit
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
October 11, 2024
Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on...
Via
Benzinga
GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations
October 10, 2024
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age group and reducing demand by two-thirds compared to last year.
Via
Benzinga
Jim Cramer Likes Reddit Very Much, Calls Accenture A 'Great Buy'
October 10, 2024
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Reddit, which went public earlier this year.
Via
Benzinga
Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday
October 09, 2024
In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication.
Via
The Motley Fool
Topics
Lawsuit
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...
Via
Benzinga
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
October 09, 2024
GSK has agreed to a $2.2 billion settlement to resolve the majority of U.S. state court Zantac lawsuits, with an additional $70 million set aside for a qui tam case. The company maintains there is no...
Via
Benzinga
Topics
Lawsuit
Merck's Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability
October 08, 2024
Merck faces a class-action lawsuit over alleged misrepresentation of its mumps vaccine potency, claiming anticompetitive practices to maintain market dominance. Despite ethical concerns, the court...
Via
Benzinga
Topics
Lawsuit
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
October 08, 2024
From
GSK plc
Via
Business Wire
Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated
October 07, 2024
Pfizer sees stock gains following a $1 billion investment by Starboard Value and a favorable UK court ruling invalidating two GSK RSV vaccine patents. Pfizer and GSK continue their legal battles as...
Via
Benzinga
Topics
Intellectual Property
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
October 07, 2024
Via
Benzinga
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
October 04, 2024
The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5...
Via
Benzinga
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
October 03, 2024
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026.
Via
Benzinga
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
October 03, 2024
Via
Investor Brand Network
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
October 03, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END
Via
FinancialNewsMedia
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon
October 01, 2024
Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.
Via
Benzinga
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
September 25, 2024
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks...
Via
Benzinga
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
September 20, 2024
Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment.
Via
MarketBeat
Topics
Economy
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
September 19, 2024
From
Alector, Inc.
Via
GlobeNewswire
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
September 18, 2024
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial results. The drug showed similar remission rates to GSK's Nucala.
Via
Benzinga
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
September 18, 2024
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The...
Via
Benzinga
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
September 18, 2024
From
GSK plc
Via
Business Wire
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
September 16, 2024
Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test.
Via
Investor's Business Daily
Topics
Death
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
September 13, 2024
The company offered a series of updates that shook shares on Thursday. The selloff continued on Friday.
Via
Investor's Business Daily
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine
September 12, 2024
GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune.
Via
Benzinga
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
September 11, 2024
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV...
Via
Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
Via
Benzinga
GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug
September 06, 2024
GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks.
Via
Benzinga
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
August 23, 2024
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.